Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Nitroglycerine 6.4 mg Tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
in a Bottle
Packaging
30 Tablets
Price
₹340/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Nitroglee 6.4 Tablet contains Nitroglycerine, an organic nitrate and potent vasodilator widely used in the prevention and management of angina pectoris. It works by releasing nitric oxide (NO), which activates guanylate cyclase in vascular smooth muscle cells, leading to increased levels of cyclic GMP and subsequent relaxation of vascular smooth muscles. This results in venodilation, reduced preload, decreased myocardial oxygen demand, and improved coronary blood flow, thereby relieving anginal symptoms. The 6.4 mg strength is typically prescribed for sustained anti-anginal therapy and prevention of angina attacks. It is not intended for immediate relief of acute chest pain but as part of maintenance therapy to reduce angina frequency and severity.
Common side effects include headache (due to cerebral vasodilation), dizziness, flushing, and hypotension. Orthostatic hypotension, reflex tachycardia, and fainting may occur, especially on sudden posture changes. Rarely, methemoglobinemia and severe allergic reactions can be seen. Tolerance can develop with prolonged continuous use; hence, a nitrate-free interval is often recommended.
Nitroglee 6.4 Tablet is indicated for the prophylaxis and long-term management of chronic stable angina pectoris and, in some cases, as adjunctive therapy in heart failure under medical supervision. It is used to reduce the frequency and intensity of angina attacks and improve exercise tolerance in patients with coronary artery disease.
Nitroglee 6.4 Tablet should only be taken under strict medical guidance. It is not for immediate relief of acute anginal attacks; sublingual nitroglycerine or sprays are recommended for acute chest pain. It is contraindicated in patients using phosphodiesterase-5 inhibitors (e.g., Sildenafil, Tadalafil) due to the risk of severe, life-threatening hypotension. Caution is advised in patients with hypotension, hypovolemia, hypertrophic cardiomyopathy, or raised intracranial pressure. Alcohol should be avoided as it can enhance vasodilatory effects and cause severe hypotension. Regular follow-up is essential to monitor response and adjust therapy as needed.
Store Nitroglee 6.4 Tablet in a tightly closed container, away from moisture, heat, and direct sunlight, as Nitroglycerine is highly volatile and sensitive to environmental conditions. Keep at a controlled room temperature (below 25–30°C). Keep out of reach of children and do not transfer to unlabelled containers.
Composition : Nitroglycerine 2.6 mg Tablet
Composition : Olmesartan Medoxomil 20 mg tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Eplerenone (50mg) tablet
Composition : Prasugrel 10 mg Tablets
Composition : Ramipril 1.25 mg tablet
Composition : Ramipril 2.5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Nitroglycerine 6.4 mg Tablet is a sustained-release vasodilator and anti-anginal medication used for the management of chronic stable angina (chest pain), coronary artery disease, and ischemic heart conditions. It works by dilating blood vessels, improving oxygen supply to the heart, and reducing cardiac workload. This makes it a key product in the cardiology and cardiovascular care segment, offering strong potential for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from steady demand from cardiologists, physicians, and hospital-based prescriptions. Since cardiovascular diseases require long-term therapy, Nitroglycerine 6.4 mg Tablet ensures consistent prescriptions, repeat purchases, and stable market growth, making it a reliable product in the cardiac segment.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiology and cardiovascular care segment with monopoly rights, quality manufacturing standards, strong promotional support, and dependable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription stability, long-term patient usage, continuous demand from cardiac care units, and institutional procurement, making it a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiology and anti-anginal formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiovascular segment.